Your browser doesn't support javascript.
loading
Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis.
Seung, Kwonjune J; Khan, Palwasha; Franke, Molly F; Ahmed, Saman; Aiylchiev, Stalbek; Alam, Manzur; Putri, Fauziah Asnely; Bastard, Mathieu; Docteur, Wisny; Gottlieb, Gary; Hewison, Catherine; Islam, Shirajul; Khachatryan, Naira; Kotrikadze, Tinatin; Khan, Uzma; Kumsa, Andargachew; Lecca, Leonid; Tassew, Yoseph Melaku; Melikyan, Nara; Naing, Ye Yint; Oyewusi, Lawrence; Rich, Michael; Wanjala, Stephen; Yedilbayev, Askar; Huerga, Helena; Mitnick, Carole D.
Afiliación
  • Seung KJ; Partners In Health, Boston, Massachusetts, USA.
  • Khan P; Interactive Research and Development, Karachi, Pakistan.
  • Franke MF; Department of Global Health and Social Medicine, Harvard Medical School and Partners In Health, Boston, Massachusetts, USA.
  • Ahmed S; Interactive Research and Development, Karachi, Pakistan.
  • Aiylchiev S; Médecins Sans Frontières, Kyrgyzstan.
  • Alam M; Interactive Research and Development, Dhaka, Bangladesh.
  • Putri FA; Interactive Research and Development, Indonesia.
  • Bastard M; Field Epidemiology Department, Epicentre, Paris, France.
  • Docteur W; Zanmi Lasante, Port-Au-Prince, Haiti.
  • Gottlieb G; Partners In Health, Boston, Massachusetts, USA.
  • Hewison C; Medical Department, Médecins Sans Frontières, Paris, France.
  • Islam S; Interactive Research and Development, Dhaka, Bangladesh.
  • Khachatryan N; Médecins Sans Frontières, Armenia.
  • Kotrikadze T; Médecins Sans Frontières, Georgia.
  • Khan U; Interactive Research and Development, Dubai, United Arab Emirates.
  • Kumsa A; Partners In Health, Addis Ababa, Ethiopia.
  • Lecca L; Socios En Salud, Lima, Peru.
  • Tassew YM; Médecins Sans Frontières, Belarus.
  • Melikyan N; Médecins Sans Frontières, Belarus.
  • Naing YY; Médecins Sans Frontières, Myanmar.
  • Oyewusi L; Partners In Health, Maseru, Lesotho.
  • Rich M; Partners In Health, Boston, Massachusetts, USA.
  • Wanjala S; Médecins Sans Frontières, Kenya.
  • Yedilbayev A; Partners In Health, Boston, Massachusetts, USA.
  • Huerga H; Field Epidemiology Department, Epicentre, Paris, France.
  • Mitnick CD; Department of Global Health and Social Medicine, Harvard Medical School and Partners In Health, Boston, Massachusetts, USA.
Clin Infect Dis ; 71(2): 415-418, 2020 07 11.
Article en En | MEDLINE | ID: mdl-31676905
ABSTRACT
Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months. Clinical Trials Registration. NCT02754765.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tuberculosis Resistente a Múltiples Medicamentos / Mycobacterium tuberculosis / Nitroimidazoles Tipo de estudio: Observational_studies Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tuberculosis Resistente a Múltiples Medicamentos / Mycobacterium tuberculosis / Nitroimidazoles Tipo de estudio: Observational_studies Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article